Trial Profile
An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs ASN 004 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 21 Feb 2024 Planned End Date changed from 31 Mar 2027 to 30 Sep 2024.
- 21 Feb 2024 Planned primary completion date changed from 31 Mar 2026 to 30 Jun 2024.
- 21 Feb 2024 Status changed from recruiting to active, no longer recruiting.